The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy
Damián Kovalovsky(United Therapeutics (United States)), Alejandro Villagra(Georgetown University)
Cited by 23
Related Papers
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
|Scientific Reports|2019|160
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
|International Journal of Molecular Sciences|2019|149